Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results.

ABSTRACT:

Background

The prognostic effect of PD-L1 status in triple-negative breast cancer (TNBC) is uncertain and little is known about PD-L1-positive prevalence and outcomes in the real-world setting.

Patients and methods

The multicentre retrospective observational VANESSA study evaluated the prevalence and impact of PD-L1-positive status in 2054 patients receiving systemic therapy for early-stage or metastatic (e/m)TNBC between 2014 and 2017. PD-L1 expression was assessed locally and centrally on archival samples. Descriptive analyses of demographic and clinicopathological characteristics, treatment patterns and clinical outcomes (extracted from patients' medical records) according to PD-L1 status were prespecified.

Results

Among 1902 patients with eTNBC, 681 (36%) received

SUBMITTER: Popovic L 

PROVIDER: S-EPMC12914666 | biostudies-literature | 2026 Apr

REPOSITORIES: biostudies-literature